Citations

Clear

2117 citation(s) found for "Mayo, Steven".

Use of Echocardiography Under Hypoxic Stress Without Exercise to Assess Right to Left Shunting
Etchegoyen, Cecilia Villa , Wraith, Rachel, Brown, Lisa , Breznak, Karen K., Mital, Rohit , Lester, Steven J., Ayoub, Chadi , Alsidawi, Said , Shipman, Justin , Farina, Juan M. , Arsanjani, Reza , Stepánek, Jan , Villa Etchegoyen, Cecilia , Wraith, Rachel E, Brown, Lisa S, Shipman, Justin N, Arsanjani, Reza , Farina, Juan M , Alsidawi, Said , Stepánek, Jan , Mital, Rohit

Mayo Clinic

Journal of Cardiovascular Development and Disease | November 3, 2025 | Volume: 12 | Issue: 11 | Pages: 435

10.3390/jcdd12110435 | PMID 41295361 Get It

Acute exposure to hypoxia will induce right ventricular (RV) hemodynamic changes and may increase the degree of right-to-left shunting, which can contribute to dyspnea at altitude. In this retrospective study, 125 patients (median age 66 years; 50.4% women) with unexplained dyspnea at altitude underwent hypoxic simulation testing (HST) with transthoracic echocardiography (TTE). During simulated hypoxia (mode (Min-Max) altitude: 8000 (6000–18,000) ft, were observed a significant decrease in oxygen saturation (97% (95–98) vs. 88% (82–92), p < 0.001) and RV free wall longitudinal strain (−19.6 ± 3.99% vs. −17.3 ± 4.17%, p < 0.01), an increase in RV systolic pressure (RVSP: 26 (23–30.5) vs. 29 (25–36.5) mmHg, p < 0.001). No significant changes were observed in TAPSE (20 (18–23) vs. 20 (19–24) mm) or S wave (0.12 (0.11–0.14) vs. 0.13 (0.12–0.14) m/s). Right-to-left shunting was present in 47.2% of patients and 11.9% exhibited inducible shunting only under hypoxia. However, under hypoxia, there were no significant differences in RV hemodynamic parameters or saturation between those with and without shunting. TTE with HST is useful to characterize both cardiopulmonary response and the dynamic changes in right-to-left shunt behavior under hypoxic stress.
Reevaluating lipoprotein(a) levels and risk of all-cause mortality in the setting of primary prevention: a retrospective cohort study
Sheashaa, Hesham, Ali, Nima Baba , Esfahani, Sogol Attaripour , Bismee, Nadera N. , Ibrahim, Omar , Abdelfattah, Fatmaelzahraa , Razaghi, Mahshad , Hafez, Abdelrahman , Ibrahim, Ramzi , Simper, David, Reddy, Satyajit , Lester, Steven J., Ayoub, Chadi , Arsanjani, Reza, Awad, Kamal , Pietri, Milagros Pereyra, Mahmoud, Ahmed K , Reddy, Satyajit T, Ayoub, Chadi , Awad, Kamal , Farina, Juan M. , Abbas, Mohammed Tiseer , Pereyra, Milagros , Scalia, Isabel G. , Mahmoud, Ahmed , Ibrahim, Ramzi , Arsanjani, Reza

Mayo Clinic

European Journal of Preventive Cardiology | October 31, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/eurjpc/zwaf700 | PMID 41183493 Get It

Comparative Outcomes of Brachyury Vaccine vs. Imatinib in Advanced Chordoma: A Mayo Clinic Experience
Llano, Juan P Navarro-Garcia de , Iyer, Harshvardhan , Hoffman, Holly , Seetharam, ­Mahesh , Attia, Steven , Navarro-Garcia de Llano, Juan P , Iyer, Harshvardhan G , Hoffman, Harry C , Akinduro, Oluwaseun O.

Mayo Clinic

Cancers | October 31, 2025 | Volume: 17 | Issue: 21 | Pages: 3493

10.3390/cancers17213493 | PMID 41228286 Get It

Background/Objectives: Chordoma, a rare slow-growing malignant bone tumor, remains therapeutically challenging due to its invasive nature. We examined institutional outcomes comparing imatinib and brachyury-directed vaccines. Methods: We used data from three sites of our quaternary care academic institution to analyze demographics, time to progression, overall survival, and adverse events in chordoma patients treated with imatinib or enrolled in a brachyury vaccine trial. Results: We included a total of 52 patients (8 in the brachyury vaccine cohort and 44 in the imatinib cohort) in the analysis. As expected, sacrococcygeal location was the most predominant in both cohorts: 62.5% in the brachyury cohort and 45.5% in the imatinib cohort. No demographic differences were present between the cohorts. ECOG was similar in both groups (p = 0.796). The primary outcome, time to progression (TTP), was shorter in the brachyury compared to the imatinib cohort (5.6 vs. 13 months, p = 0.0589), almost reaching statistical significance. Overall survival (OS) was comparable, 211 vs. 212 months for the brachyury and imatinib cohorts, respectively (p = 0.277). Although the brachyury vaccine cohort presented a higher incidence of adverse events than the imatinib cohort (75% vs. 31.8%, p = 0.021), the severity was milder. Conclusions: Imatinib showed longer disease control than the brachyury vaccine, though overall survival was similar. Future studies and deeper molecular insights are essential to develop better therapies and improve patient quality of life.
SUN-163 45,X/46,X,Idic(Y)(q11.21) Mosaicism in a Nonbinary Individual Receiving Gender-Affirming Hormone Therapy Before Orchiectomy
Thota-Kammili, Sanjana , Peres, Steven, Edgar, Mark , Chang, Alice Y. , McNeil, J Anderson, Reynolds, Jordan , Eleazer, Jacob

Mayo Clinic

Journal of the Endocrine Society | October 23, 2025 | Volume: 9 | Issue: Supplement_1 | Pages: No page available

10.1210/jendso/bvaf149.2094 Get It

Abstract Disclosure: S. Thota-Kammili: None. J.A. McNeil: None. S.J. Peres: None. M.A. Edgar: None. J.P. Reynolds: None. J. Eleazer: None. A.Y. Chang: None. Introduction: 45,X/46,X,psrY mosaicism has been reported in the context of prenatal diagnosis with few reports on the developmental phenotype through adulthood. The 45,X/46,XY karyotype is well-studied and linked to ambiguous genitalia, dysgenetic gonads, and increased gonadal tumor risk. Less is known about 45,X/46,X,psrY mosaicism, characterized by partial Y chromosome retention. Phenotypic variability with a broad spectrum of phenotypes including Turner syndrome features, delayed puberty, hypogonadism and infertility depends on the extent and functionality of preserved Y chromosome material. We present a case of 45,X/46,X,idic(Y)(q11.21) mosaicism in an individual assigned male at birth, with a nonbinary intersex gender identity who received gender affirming feminizing hormone therapy (GAHT) before orchiectomy. Clinical Case: This is a case of a 36 y.o. patient who was found to have 45,X/46,X +mar chromosomal abnormality prenatally and initially diagnosed with Turner’s syndrome. At birth, patient had male genitalia, descended testes, and only slight hypospadias. Subsequent Y-DNA studies determined the unknown marker to be the sex determining region of the Y chromosome. Early evaluations showed appropriate responses to LHRH and ACTH, and developmental milestones were met without major health or behavioral concerns aside from a delay in puberty. The patient experienced early gender incongruence and faced questioning for gender expression. Delayed puberty led to testosterone therapy, worsening distress. Parents did not share the medical history with the patient until adulthood, when they notified them about the potential for infertility. During infertility evaluation, semen analysis revealed azoospermia. Testosterone therapy was re-attempted for hypogonadism but resulted in increased distress and patient began GAHT. Patient sought a second opinion on previous diagnosis of differences of sexual development (DSD). Chromosomal analysis revealed the 45,X/46,X,idic(Y)(q11.21) mosaicism, with duplication of Yp and deletion of the Yq. Pt was referred to urology for bilateral orchiectomy to reduce gonadal tumor risk and gender dysphoria. Pathology revealed atrophic seminiferous tubules with complete absence of spermatogenesis which were populated by Sertoli cells only and surrounded by thickened basal lamina. Leydig cells were markedly depleted. These changes are seen in transgender patients treated with estrogen prior to orchiectomy. Conclusion: Our case expands the phenotypic characterization of 45,X/46,X,idic(Y)(q11.21) mosaicism by detailing clinical features and previously unreported testicular pathology. This patient had minimal developmental concerns, and testicular pathology reflected changes associated with GAHT, highlighting the variability in phenotypic expression of 45,X/45,X,psrY mosaicism. Presentation: Sunday, July 13, 2025
SAT-458 Mifepristone-induced gynecomastia, hyperestrogenemia, and secondary hypogonadism in a male with primary bilateral macronodular adrenal hyperplasia
Gil, Adrian Marcelo Gonzalez, Elli, Enrique F. , Singh, Ravinder Jit, Peres, Steven, Chang, Alice Y. , Singh, Ravinder Jit

Mayo Clinic

Journal of the Endocrine Society | October 23, 2025 | Volume: 9 | Issue: Supplement_1 | Pages: No page available

10.1210/jendso/bvaf149.326 Get It

Abstract Disclosure: A.M. Gonzalez Gil: None. E.F. Elli: None. R.J. Singh: None. S. Peres: None. A.Y. Chang: None. Background: Treatment of hypercortisolism in primary bilateral macronodular adrenal hyperplasia (PBMAH) with mild autonomous cortisol secretion (MACS) can be challenging. Medical treatment is useful for therapeutic purposes and as a bridge for adrenalectomy. We present the case of a patient who benefited from mifepristone but developed hyperestrogenism. Clinical Case: A 64-year-old man with prediabetes, hypertension, and cardiovascular disease had incidentally discovered bilateral nodular adrenal enlargement on CT scan following coronary artery bypass surgery. A few months later, he reported increasing fatigue, brain fog, weight gain, and worsening blood pressure. Physical exam showed no features of hypercortisolism. Work-up revealed baseline AM cortisol 17.3 mcg/dL [reference range (RR) 4.8-20], ACTH 10 pg/mL (RR 7.2-63) and DHEA-S 55 mcg/dL (RR 12-227); two abnormal AM cortisols after 1 mg overnight dexamethasone (5.4 and 6.9 mcg/dL; cut-off &lt;1.8), and a normal 24-hour urine free cortisol (23 mcg/24h, RR 3.5-45). 24-hour urine metanephrines and aldosterone/renin ratio were normal. A 2-hour 75 g oral glucose tolerance test was diagnostic for type 2 diabetes mellitus (2-hour glucose 214 mg/dL). Baseline total testosterone (TT) was 366 ng/dL (RR 264-916) with normal follicle stimulating hormone (FSH) and luteinizing hormone (LH)concentrations. After a diagnosis of MACS, adrenal vein sampling showed bilateral excess cortisol secretion (lateralization ratio 1.09). Medical management versus right adrenalectomy based on nodule burden were offered, and he started mifepristone. With initial symptom improvement, his dose was increased from 300 mg to 300 mg alternating with 600 mg daily. When he developed increased blood pressure and hypokalemia, eplerenone was added. After 6 months of mifepristone and 5 months eplerenone 50 mg daily, he developed tender gynecomastia with elevated estradiol (106 pg/mL, RR ≤39), low TT (112 ng/dL) and undetectable FSH and LH. As expected with mifepristone, 17-hydroxyprogesterone was high (933 ng/dL, RR 51-190), but androstenedione and DHEA-S were normal. Reduction in mifepristone and eplerenone decreased estradiol levels (56 pg/mL) but gonadotrophins remained undetectable and TT decreased to 72 ng/dL. Despite discontinuation of eplerenone for 1 month, estradiol again increased (91 pg/mL), TT remained low (77 ng/dL), and mastalgia persisted. A decision to stop mifepristone and proceed with right adrenalectomy was made. Conclusion: This is a previously unreported incident of symptomatic estradiol-induced secondary hypogonadism on mifepristone therapy. Hyperestrogenism with gynecomastia and secondary hypogonadism with mifepristone suggests that some individuals may convert cortisol precursors to estradiol. Presentation: Saturday, July 12, 2025
Efficacy and Safety of Long-Term Continuous Nirogacestat Treatment in Adults With Desmoid Tumors: Results From the DeFi Trial
Ratan, Ravin , Kasper, Bernd , Alcindor, Thierry , Schöffski, Patrick , Graaf, Winette T.A. van der , Federman, Noah , Bui, Nam Q. , D’Amato, Gina Z. , Riedel, Richard F. , Attia, Steven , Chawla, Sant P. , Lim, Allison , Oton, Ana B. , Chu, Yucheng, Zhou, Shengfan , Gounder, Mrinal M. , van der Graaf, Winette T A , Tumminello, Brad , Gounder, Mrinal , Riedel, Richard F , Bui, Nam , Zhou, Shengfan

Mayo Clinic

Journal of Clinical Oncology | October 20, 2025 | Volume: 43 | Issue: 34 | Pages: 3646-3651

10.1200/jco-25-00582 | PMID 41115259 Get It

In the phase III placebo-controlled DeFi trial (ClinicalTrials.gov identifier: NCT03785964 ) primary analysis, nirogacestat showed significant improvement versus placebo in progression-free survival (PFS), objective response rate (ORR), and patient-reported outcomes (PRO) in adult patients with progressing desmoid tumors (DT; median [range] exposure: 20.6 [0.3-33.6] months). Here, long-term nirogacestat efficacy and safety were evaluated in patients randomly assigned to nirogacestat and followed through the final data cutoff date of December 19, 2024. End points included PFS and ORR per RECIST v1.1, PRO, and safety. The median (range) duration of exposure was 33.6 (0.3-61.8) months. Median PFS was not reached. The ORR with up to 4 years of nirogacestat treatment was 45.7% (32 of 70), with three additional partial and three additional complete responses since the primary analysis. Further target tumor size reduction occurred in most patients. Benefits in PROs were sustained while on treatment. Frequently reported treatment-emergent adverse events (TEAEs) decreased in incidence and severity over time. Since the primary analysis, four patients discontinued nirogacestat because of TEAEs between years 2 and 4. In conclusion, long-term continuous nirogacestat treatment was associated with further tumor size reductions, durable objective responses, sustained PRO benefits, and a manageable safety profile consistent with the primary analysis.
Preoperative Antiplatelet Drugs do not Increase the Risk of Spinal Hematoma Associated with Regional Anesthesia
Horlocker, Terese T. , Wedel, Denise J., Offord, K. P., Rose, Steven H., Elliott, Beth A., McGregor, D. G., Wong, Gilbert Y.

Mayo Clinic

Regional Anesthesia: The Journal of Neural Blockade in Obstetrics, Surgery, & Pain Control | October 11, 2025 | Volume: 19 | Issue: Suppl 2 | Pages: 8-8

10.1136/rapm-00115550-199419021-00008 Get It

Regional anesthesia facilitates fistula creation over graft in patients with small-caliber veins: A single-center cohort
Alsabbagh, Yaman , Jlilati, Adeeb , Sarmiento, Joaquin, Lanka, Santh Prakash , Robards, Christopher B., Clendenen, Steven R. , Vandenberg, Jonathan , Jacobs, Christopher R. , Farres, Houssam , Ardon, Alberto E, Jacobs, Christopher, Jlilati, Adeeb , Erben, Young , Ardon, Alberto E. , Jacobs, Christopher

Mayo Clinic

The Journal of Vascular Access | October 8, 2025 | Volume: 27 | Issue: 3 | Pages: 1031-1037

10.1177/11297298251382268 | PMID 41058214 Get It

Objective: To evaluate the efficacy of regional anesthesia (RA) in enabling arteriovenous fistula (AVF) creation in patients with small-caliber veins who would typically receive arteriovenous grafts (AVG), and to compare access outcomes between AVF and AVG cohorts. Methods: We conducted a retrospective analysis of a prospectively maintained database from 2018 through 2024 involving patients with chronic kidney disease (CKD) requiring access creation. Eligible patients were those aged 18 years or older with inadequate veins for AVF creation based on initial ultrasound vein mapping. All patients underwent RA prior to the access creation and had a repeated intraoperative vein mapping at least 30 min after RA. Patients whose veins were sufficiently dilated and met the criteria for AVF creation underwent AVF formation; otherwise, an AVG was created. Outcomes included access maturation, patency rates, access failure, abandonment, and mortality. Statistical analysis was performed using R software, with significance set at p < 0.05. Results: Of the 106 patients, 67 (63.2%) underwent AVF creation post-RA due to sufficient vein dilation, while 39 (36.8%) received AVGs. Baseline vein diameters and comorbidities were comparable between groups. AVF maturation was achieved in 83.6% of AVF patients, with longer times to successful cannulation compared to AVG (median 187.0 vs 80.0 days, p = 0.037). Kaplan-Meier analysis revealed no difference in primary patency ( p = 0.97), but AVF patients had superior primary assisted ( p = 0.015) and secondary patency ( p = 0.033), and lower access failure rates ( p = 0.034) compared to AVG patients. Access abandonment and mortality rates did not differ significantly between groups. Conclusions: RA-induced venodilation enables the use of veins previously deemed inadequate for AVF creation, leading to improved access outcomes compared to AVG placement. Implementing RA may increase AVF utilization and enhance patient outcomes in hemodialysis access surgery.
SGLT2 Inhibitors in Heart Failure with Reduced Ejection Fraction: A Retrospective Cohort Analysis of Sex - Specific Cardiovascular Outcomes
Ibrahim, Ramzi , Al-Asmar, Rahmeh, AlHammouri, Hashim M. , Abdelnabi, Mahmoud , Forst, Beani, Sarkis, Patrick , Lester, Steven J., Rosenthal, Julie , Ibrahim, Ramzi , Al-Asmar, Rahmeh , Pham, Hoang Nhat , Lee, Kwan , Arsanjani, Reza

Mayo Clinic

Current Cardiology Reviews | October 6, 2025 | Volume: 22 | Issue: 4 | Pages: No page available

10.2174/011573403x394902250911111958 | PMID 41047672 Get It

Introduction: Sex-based differences in outcomes among patients with heart failure with reduced ejection fraction (HFrEF) treated with sodium-glucose cotransporter 2 inhibitors (SGLT2is) remain underexplored. This study aimed to evaluate sex-specific differences in cardiovascular outcomes in patients with HFrEF receiving SGLT2 inhibitors alongside guidelinedirected medical therapy (GDMT). Methods: We conducted a retrospective cohort study using the TriNetX global research network. Adults with HFrEF treated with SGLT2is and GDMT were stratified by sex. Propensity score matching (PSM) was used to balance baseline demographics, comorbidities, medications, and laboratory data. Primary outcomes were all-cause mortality and acute heart failure (HF) events; secondary outcomes included hospitalizations, arrhythmias, renal outcomes, and advanced therapies. Results: After PSM, 17,408 male and 17,408 female patients were analyzed. Male patients had lower odds of acute HF events (aOR: 0.949; 95% CI: 0.909–0.991), all-cause hospitalizations (aOR: 0.933; 95% CI: 0.895–0.973), and renal failure (aOR: 0.915; 95% CI: 0.870–0.962). No significant differences were observed in all-cause mortality (aOR: 1.003; 95% CI: 0.926–1.087) or heart transplantation, although LVAD use was more frequent in males (aOR: 1.416; 95% CI: 1.053–1.905). Discussion: The findings highlighted potential sex-based disparities in outcomes for patients with HFrEF on SGLT2is. Differential prescribing patterns, comorbidity burden, or timing of therapy initiation may contribute to observed differences. Conclusion: Among HFrEF patients treated with SGLT2is, males experienced lower risks of HF events, hospitalizations, and renal failure compared to females, despite similar mortality. Further research is needed to understand and address sex-specific disparities in HFrEF management.
The Definition of Cure in Colon Cancer
Pastorino, Alessandro , Liu, Heshan , Pederson, Levi , Martelli, Valentino , Gramont, Aimery de , Harkin, Andrea , Twelves, Chris , Souglakos, Ioannis , Goldberg, Richard M. , Puccini, Alberto , Sobrero, Alberto , Group, ACCENT/IDEA, Iveson, Timothy , Alberts, Steven R. , George, Thomas J. , Yothers, Greg , Labianca, Roberto , Taı̈eb, Julien , Schmoll, Hans‐Joachim , Wolmark, Norman , Saltz, Leonard B. , Goldberg, Richard M. , Kerr, Rachel , Lonardi, Sara , Yoshino, Takayuki , André, Thierry , Shi, Qian , Group, ACCENT/IDEA

Mayo Clinic

JAMA Oncology | October 2, 2025 | Volume: 11 | Issue: 12 | Pages: 1440

10.1001/jamaoncol.2025.3760 | PMID 41037274 Get It

Importance The definition of cure in stage II to III colon cancer (CC) remains unclear due to limitations in conventional end points, which include deaths and second primary tumors as events. These can complicate communication with patients regarding long-term outcomes. Objective To distinguish relapses from competing health-related events to classify long-term outcomes years after surgery and explore when the incidence of true relapses of the initial CC approaches 0% to define cure in this disease. Design, Setting, and Participants This pooled analysis of individual patient–level data from 15 phase 3 randomized clinical trials assessed time to CC-related relapse using Kaplan-Meier and Aalen-Johansen methods, with death and second primary tumors treated as competing risks. Cox regression models evaluated prognostic associations, stratified by sex, stage, and tumor. Patients with stage II to III CC who underwent adjuvant chemotherapy were included. All patients had undergone radical surgery for CC and received adjuvant chemotherapy with a median follow-up of at least 6 years. The Adjuvant Colon Cancer Endpoints (ACCENT) and the International Duration Evaluation of Adjuvant Chemotherapy (IDEA) databases included adjuvant studies conducted between 1996 and 2015. Data were analyzed from February 2022 to June 2025. Exposures Adjuvant chemotherapy regimens varied across trials, including fluoropyrimidines alone or in combination with oxaliplatin or biologic agents. Main Outcomes and Measures The primary outcome was time to CC-related recurrence. The predefined threshold for cure was a recurrence risk below 0.5%. Results Of 35 213 included patients, 19 346 (54.9%) were male, and the mean (SD) age was 60.2 (10.8) years. The incidence rate of recurrence peaked at 6.4% (1993 of 31 373) between month 6 and month 12 and decreased continuously until year 10 of follow-up never exceeding 0.5%. Recurrence rate appeared to increase again after year 10 and peaked at 2.0% during year 12.5 to year 13, a pattern observed exclusively in the MOSAIC trial. Competing-event analysis revealed that death and second primary tumors inflated the apparent recurrence rate, especially for older patients. The overall cumulative incidence of relapse with death as competing risk was lower among female patients (hazard ratio, 0.58; 95% CI, 0.45-0.76; P &amp;lt; .001). Conclusions and Relevance In this pooled analysis of phase 3 randomized clinical trials, a recurrence rate less than 0.5% occurred after 6 years from surgery, supporting a practical definition of cure. Recognizing this milestone may improve patient communication, guide follow-up duration, and reduce unnecessary long-term surveillance.